Download full-text PDF |
Source |
---|
iScience
January 2025
Department of Vascular Surgery, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Aging is accompanied by a decline in neovascularization potential and increased susceptibility to ischemic injury. Here, we confirm the age-related impaired neovascularization following ischemic leg injury and impaired angiogenesis. The age-related deficits in angiogenesis arose primarily from diminished EC proliferation capacity, but not migration or VEGF sensitivity.
View Article and Find Full Text PDFComb Chem High Throughput Screen
January 2025
Biomedical Sciences College & Shandong Medicinal Biotechnology Centre, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Objective: This study aimed to investigate the effect of angelicin on the NSCLC tumor growth.
Background: Accumulating evidence shows that cancer-associated fibroblasts (CAFs) play an important role in tumor progression and metastasis, making CAFs an increasingly attractive target for therapeutic intervention. Targeted therapies against CAFs have been considered to have the potential to significantly improve cancer treatment outcomes, overcome resistance, and improve immune evasion.
Aliment Pharmacol Ther
January 2025
Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Background: Obesity has been linked to a more severe phenotype in patients with ulcerative colitis (UC).
Aim: To evaluate the impact of obesity on outcomes of advanced therapies in UC.
Methods: We conducted a retrospective cohort study utilising the TriNetX database comparing the composite score of corticosteroid use, change in advanced therapy or colectomy within two years between two cohorts of patients with UC-those with obesity (BMI ≥ 30 kg/m) and those without (BMI 18.
Cureus
December 2024
Department of Pathology and Medical Laboratory, Faculty of Medicine, Universiti Sultan Zainal Abidin, Kuala Terengganu, MYS.
Lewis antibodies, such as anti-Le and anti-Le, are commonly encountered in routine immunohematology. They are typically IgM in nature and are generally considered clinically insignificant, as they rarely cause hemolytic transfusion reactions (HTRs) or hemolytic disease of the fetus and newborn (HDFN). However, rare cases have been reported where anti-Lewis antibodies caused mild transfusion reactions.
View Article and Find Full Text PDFMol Syst Biol
January 2025
Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany.
The DNA-damaging agent Gemcitabine (GEM) is a first-line treatment for pancreatic cancer, but chemoresistance is frequently observed. Several clinical trials investigate the efficacy of GEM in combination with targeted drugs, including kinase inhibitors, but the experimental evidence for such rationale is often unclear. Here, we phenotypically screened 13 human pancreatic adenocarcinoma (PDAC) cell lines against GEM in combination with 146 clinical inhibitors and observed strong synergy for the ATR kinase inhibitor Elimusertib in most cell lines.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!